Advertisement

Agents and Actions

, Volume 24, Issue 1–2, pp 114–119 | Cite as

Leukotriene B4 and inflammatory disease

  • R. M. McMillan
  • S. J. Foster
Immunosuppression and Inflammation Editorial

Abstract

Polymorphonuclear leukocytes (PMNL) are prominent at sites of acute inflammation. Their infiltration is stimulated under pathological conditions by a variety of agents which include bacteria, immune complexes and complement derived chemotactic peptides. Recently attention was focussed on the 5-lipoxygenase product leukotriene B4 (LTB4) which has been demonstrated to induce the key features associated with an acute inflammatory reaction. However, evidence supporting a pro-inflammatory role for LTB4, and therefore the anti-inflammatory efficacy of 5-lipoxygenase inhibitors, is largely circumstantial. Moreover, there are concerns that other chemotactic factors, notably C5a, may compensate for the absence of LTB4. Here we challenge this view and, on the basis of recent experimental and clinical data suggest that LTB4 does not simply duplicate the activity of C5a. Instead we propose that their predominant site(s) of action differ in such a way that they may synergise in mediating PMNL recruitment.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    A. W. Ford-Hutchinson, M. A. Bray, M. V. Doig, M. E. Shipley and M. J. H. Smith,Leukotriene B: a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature286, 264–265 (1980).PubMedGoogle Scholar
  2. [2]
    T. E. Rollins, B. Zanolari, M. S. Springer, Y. Guindon, R. Zamboni, C.K. Lau and J. Rokach,Synthetic leukotriene B 4 is a potent chemotaxin but a weak secretagogue for human PMN. Prostaglandins25, 281–289 (1983).PubMedGoogle Scholar
  3. [3]
    H. J. Showell, P. H. Naccache, P. Borgeat, S. Picard, P. Vallerand, E. L. Becker and R. I. Sha'afi,Characterization of the secretory activity of leukotriene B 4 toward rabbit neutrophils. J. Immunol.128, 811–816 (1982).PubMedGoogle Scholar
  4. [4]
    J. Palmblad, C. L. Malmsten, A.-M. Uden, O. Radmark, L. Engstedt and B. Samuelsson,LTB 4 is a potent stereospecific stimulator of neutrophil chemotaxis and adherence. Blood58, 658–661 (1981).PubMedGoogle Scholar
  5. [5]
    E. J. Geotzl and W. C. Picket,The human polymorphonuclear leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETE'S). J. Immunol.125, 1789–1791 (1980).PubMedGoogle Scholar
  6. [6]
    R. A. Lewis, E. J. Goetzel, J. M. Drazen, N. A. Soter, K. F. Austen and E. J. Corey,Functional characterization of synthetic leukotriene B 4 and its stereochemical isomers. J. Exp. Med.154, 1243–1248, (1981).PubMedGoogle Scholar
  7. [7]
    A. W. Ford-Hutchinson, A. Rackham, R. Zamboni, J. Rokach and S. Roy,Comparative biological activities of synthetic leukotriene B 4 and its w-oxidation products. Prostaglandins25, 29–37 (1983).PubMedGoogle Scholar
  8. [8]
    R. A. Kreisle and C. W. Parker,Specific binding of leukotriene B 4 to a receptor on human polymorphonuclear leukocytes. J. Exp. Med.157, 628–641 (1983).PubMedGoogle Scholar
  9. [9]
    D. W. Goldman and E. J. Goetzl,Heterogeneity of human polymorphonuclear leukocyte receptors for leukotriene B 4. J. Exp. Med.159, 1027–1041 (1984).PubMedGoogle Scholar
  10. [10]
    D. W. Goldman, L. A. Gifford, D.M. Olson, and E. J. Goetzl,Transduction by leukotriene B 4 receptors of increases in cytosolic calcium in human polymorphonuclear leukocytes. J. Immunol.135, 525–530 (1985).PubMedGoogle Scholar
  11. [11]
    D. W. Goldman, L. A. Gifford, T. Marotti, C. H. Koo and E. J. Goetzl,Molecular and cellular properties of human polymorphonuclear leukocyte receptors for leukotriene B 4. Federation Proc.46, 200–203 (1987).Google Scholar
  12. [12]
    R. Synderman and E. J. Goetzl,Molecular and cellular mechanisms of leukocyte chemotaxis. Science213, 830–837 (1981).PubMedGoogle Scholar
  13. [13]
    P. Bhattacherjee, K. E. Eakins and B. Hammond,Chemotactic activity of arachidionic acid and lipoxygenase products in the rabbit eye. Br. J. Pharmac.73. 254P (1981).Google Scholar
  14. [14]
    M. A. Bray, A. W., Ford-Hutchinson and M. J. H. Smith,Leukotriene B 4:an inflammatory mediator in vivo. Prostaglandins22, 213–222 (1981).PubMedGoogle Scholar
  15. [15]
    N. C. Staub, E. L. Schultz, K. Koike and K. H. Albertine.Effect of neutrophil migration induced by leukotriene B 4 on protein permeability in sheep lung. Fedn. Proc.44, 30–35 (1985).Google Scholar
  16. [16]
    M. J. H. Smith, A. W. Ford-Hutchinson and M. A. Bray,Leukotriene B: a potential mediator of inflammation. J. Pharm. Pharac.32, 517–518 (1980).Google Scholar
  17. [17]
    N. A. Soter, R. A. Lewis, E. J. Corey, and K. F. Austen,Local effects of synthetic leukotrienes (LTC 4,LTD 4 LTE 4 and LTB 4)in human skin. J. Invest. Dermatol.80, 115–119 (1983).PubMedGoogle Scholar
  18. [18]
    R. Camp, R. R. Jones, S. Brain, P. Woolard and M. Greaves,Production of intraepidermal microabscesses by topical application of leukotriene B 4 J. Invest. Dermatol.84, 427–429 (1985).PubMedGoogle Scholar
  19. [19]
    C. V. Wedmore and T. J. Williams,Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature289, 646–650 (1981).PubMedGoogle Scholar
  20. [20]
    M. J. Forrest, P. J. Jose and T. J. Williams,Kinetics of the generation and action of chemical mediators in zymosan-induced inflammation of the rabbit peritoneal cavity. Br. J. Pharmac.89, 719–730 (1986).Google Scholar
  21. [21]
    L. Lindbom, P. Hedqvist, S.-E. Dahlen, J. A. Lindgren and K.-E. Arfors,Leukotriene B 4 induces extravasation and migration of polymorphonuclear leukocytes in vivo. Acta. Physiol. Scand.116, 105–108 (1982).PubMedGoogle Scholar
  22. [22]
    R. M. J. Palmer and J. A. Salmon,Release of leukotriene B 4 from human neutrophils and its relationship to degranulation induced by N-formylmethionyl-leucyl-phenylalanine, serumtreated zymosan, and the ionophore A23187. Immunology50, 65–73 (1983).PubMedGoogle Scholar
  23. [23]
    P. A. J. Henricks, M. E. Van der Tol, F. Engels, F. P. Nijkamp and J. Verhoef,Human polymorphonuclear leukocytes release leukotriene B 4 during phagocytosis of Staphylococcus aureus. Inflammation10, 37–47 (1986).PubMedGoogle Scholar
  24. [24]
    R. M. Clancy, C. A. Dahinden and T. E. Hugli,Arachidonate metabolism by human polymorphonuclear leukocytes stimulated with N-formyl-met-leu-phe or complement component C 5 a is independent of phospholipase activation. Proc. Nat. Acad. Sci. U.S.A.80, 7200–7204 (1983).Google Scholar
  25. [25]
    J. O. Williams, T. H. Lee, R. A. Lewis and F. Austen,Intracellular retention of the 5-lipoxygenase pathway product, leukotriene B 4,by human neutrophils activated with unopsonised zymosan. J. Immunol.134, 2624–2630 (1985).PubMedGoogle Scholar
  26. [26]
    W. Seeger, N. Suttorp, A. Hellwig and S. Bhadki,Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B 4 generation in human polymorphonuclear leukocytes. J. Immunol.137, 1286–1293 (1986).PubMedGoogle Scholar
  27. [27]
    J. D. Williams, J. K. Czop and K. F. Austen,Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators. J. Immunol.132, 3034–3040 (1984).PubMedGoogle Scholar
  28. [28]
    M. E. Goldyne, G. F. Burrish, P. Poubelle and P. Borgeat,Arachidonic acid metabolism among human mononuclear leukocytes: lipoxygenase related pathways. J. Biol.-Chem.259, 8815–8819 (1984).PubMedGoogle Scholar
  29. [29]
    R. J. Bonney, E. E. Opas and J. L. Humes,Lipoxygenase pathways of macrophages. Fed. Proc.44, 2933–2936 (1985).PubMedGoogle Scholar
  30. [30]
    P. M. Simmons, J. A. Salmon and S. Moncada,The release of leukotriene B 4 during experimental inflammation. Biochem. Pharmac.32, 1353–1359 (1983).Google Scholar
  31. [31]
    D. M. Aked and S. J. Foster,Leukotriene B 4 and acute inflammation in the rabbit. Br. J. Pharmac.90, 235P (1987).Google Scholar
  32. [32]
    A. D. Sedgwick and P. Lees,Studies of eicosanoid production in the air pouch model of synovial inflammation. Agents and Actions18, 429–438 (1986).PubMedGoogle Scholar
  33. [33]
    S. J. Foster, M. E. McCormick, A. Howarth and D. Aked,Leukocyte recruitment in the subcutaneous sponge implant model of acute inflammation in the rat is not mediated by leukotriene B 4 Biochem. Pharmac.35, 1709–1717 (1986).Google Scholar
  34. [34]
    D. E. Kopp, B. Esser, T. Tashoff, D. W. Goldman, E. J. Goetzl and R. F. Lemanske,In vivo and in vitro assessment of the role of leukotriene B 4 as a mediator of rat cutaneous late-phase reactions. J. Allergy and Clin. Immunol.77, 302–308 (1986).Google Scholar
  35. [35]
    R.A. Kreisle, C. W. Parker, G. L. Griffin, R. M. Senior and W. F. Stenson,Studies of leukotriene B 4-specific binding and function in rat polymorphonuclear leukocytes: absence of a chemotactic response. J. Immunol.134, 3356–3363 (1985).PubMedGoogle Scholar
  36. [36]
    G. A. Higgs, J. A. Salmon and J. A. Spayne,The inflammatory effects of hydroperoxy and hydroxy acid products of arachidonate lipoxygenase in rabbit skin. Br. J. Pharmac.74 429–433 (1981).Google Scholar
  37. [37]
    H. Z. Movat, C. Rettl, C. E. Burrowes, and M. G. Johnston,The in vivo effect of leukotriene B 4 on polymorphonuclear leukocytes and the microcirculation. Am. J. Pathol.115, 233–244 (1984).PubMedGoogle Scholar
  38. [38]
    D. Aked, S. J. Foster, A. Howarth, M. E. McCormic and H. C. Potts,The inflammatory response of rabbit skin to topical arachidonic acid and its pharmacological modulation. Br. J. Pharmac.89, 431–438 (1986).Google Scholar
  39. [39]
    D. M. Aked and S. J. Foster,The contribution of eicosanoids to the acute inflammatory reaction induced by arachidonic acid in rabbit skin. Br. J. Pharmac.90, 58P (1987).Google Scholar
  40. [40]
    D. M. Aked and S. J. Foster,Leukotriene B 4 and prostaglandin E 2 mediate the inflammatory response of rabbit skin to intradermal arachidonic acid. Br. J. Pharmac.92, 545–552 (1987).Google Scholar
  41. [41]
    S. A. Raé, E. M. Davidson and M. J. H. Smith,Leukotriene B 4,an inflammatory mediator in gout. Lancetii, 1122–1124 (1982).Google Scholar
  42. [42]
    R. M. McMillan, S. J. Foster and P. A. Dieppe,Leukotriene B 4 metabolism in human leukocytes: fact or artefact? Agents and Actions21, 1–3 (1987).Google Scholar
  43. [43]
    S. Shak and I. M. Goldstein,w-oxidation is the major pathway for the catabolism of leukotriene B 4 in human polymorphonuclear leukocytes. J. Biol. Chem.259, 10181–10187 (1984).PubMedGoogle Scholar
  44. [44]
    P. A. Simkin and K.-L. Nilson,Trans-synovial exchange of large and small molecules. In:clinics in rheumatic diseases, Vol. 7. The biology of the joint, pp. 99–129 (Ed. P. Hasselbacher), W. B. Saunders Co. Ltd., London (1981).Google Scholar
  45. [45]
    M. G. Tonnesen, L. Smedly, A. Goins and P. M. Henson,Interaction between neutrophils and vascular endothelial cells. In: Agents and Actions, Suppl., Cologne Atherosclerosis Conference XI, pp. 25–38 (Eds. M. J. Parnham and J. Winkelmann) Birkhäuser Verlag, Basel (1982).Google Scholar

Copyright information

© Birkhäuser Verlag 1988

Authors and Affiliations

  • R. M. McMillan
    • 1
  • S. J. Foster
    • 1
  1. 1.Pharmaceuticals Division, Bioscience I Department, MeresideImperial Chemical Industries PLCMacclesfieldU.K.

Personalised recommendations